Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer

Long noncoding RNAs (lncRNAs) have been characterized to play an essential role in ovarian tumorigenesis via controlling a variety of cellular processes, such as cell proliferation, invasion, apoptotic death, metastasis, cell cycle, migration, metabolism, immune evasion, and chemoresistance. The one obstacle for the therapeutic efficacy is due to the development of drug resistance in ovarian cancer patients. Therefore, in this review article, we describe the role of lncRNAs in chemoresistance in ovarian cancer. Moreover, we discuss the molecular mechanism of lncRNAs-involved drug resistance in ovarian cancer. We conclude that lncRNAs could be useful targets to overcome chemoresistance and improve therapeutic outcome in ovarian cancer patients.

[1]  GuanNing Shang,et al.  Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma , 2022, Frontiers in Oncology.

[2]  Yuwei Chen,et al.  Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer , 2022, Bioengineered.

[3]  Jianfa Wu,et al.  CRNDE inducing cisplatin resistance through SRSF1/TIA1 signaling pathway in ovarian cancer. , 2022, Pathology, research and practice.

[4]  Qiaojun He,et al.  Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. , 2022, European journal of pharmacology.

[5]  S. Horibata,et al.  Mechanisms of chemotherapy resistance in ovarian cancer , 2022, Cancer drug resistance.

[6]  Ling-Fei Zhu,et al.  Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a , 2022, Bioengineered.

[7]  Zhi-wei Wang,et al.  Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers. , 2022, Pharmacology & therapeutics.

[8]  Yingmei Wang,et al.  Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review). , 2022, Oncology reports.

[9]  K. Steffensen,et al.  The Long Non-Coding RNA SNHG12 as a Mediator of Carboplatin Resistance in Ovarian Cancer via Epigenetic Mechanisms , 2022, Cancers.

[10]  GuanNing Shang,et al.  The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets , 2022, Frontiers in Cell and Developmental Biology.

[11]  A. Jemal,et al.  The Changing Landscape of Gynecologic Cancer Mortality in the United States , 2022, Obstetrics and gynecology.

[12]  Mingxiao Cui,et al.  Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. , 2022, European journal of medicinal chemistry.

[13]  Kecheng Zhang,et al.  Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer , 2022, Journal of Ovarian Research.

[14]  Hui Zhang,et al.  Noncoding RNAs Interplay in Ovarian Cancer Therapy and Drug Resistance. , 2022, Cancer biotherapy & radiopharmaceuticals.

[15]  H. Feng,et al.  KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer. , 2022, Life sciences.

[16]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[17]  M. M. S. Socías Viciana,et al.  Declaration of Competing Interestthe Authors Declare that They Have No Known Competing Financial Interests or Personal Relationships that Could Have Appeared to Influence the Work Reported in this Paper , 2022, SSRN Electronic Journal.

[18]  Changlei Su,et al.  LncRNA TCF7 Promotes Epithelial Ovarian Cancer Viability, Mobility and Stemness via Regulating ITGB8 , 2021, Frontiers in Oncology.

[19]  Jin Zhang,et al.  Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant , 2021, Bioengineered.

[20]  M. Fan,et al.  LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[21]  Zhi-wei Wang,et al.  The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy , 2021, Molecular cancer.

[22]  S. Xiao,et al.  The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer , 2021, Frontiers in Genetics.

[23]  Feikai Lin,et al.  Ovarian cancer: epigenetics, drug resistance, and progression , 2021, Cancer cell international.

[24]  Lan Xiao,et al.  Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway , 2021, Journal of gynecologic oncology.

[25]  Mei Zhang,et al.  LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis , 2021, Cancer Cell International.

[26]  Yang Yang,et al.  YY1-Induced lncRNA PART1 Enhanced Resistance of Ovarian Cancer Cells to Cisplatin by Regulating miR-512-3p/CHRAC1 Axis. , 2021, DNA and cell biology.

[27]  C. Maher,et al.  Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.

[28]  Ying Chen,et al.  Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway. , 2021, Clinical immunology.

[29]  Lianhui Qi,et al.  Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis , 2021, Anti-cancer drugs.

[30]  Yun Dai,et al.  LncRNA TRPM2-AS promotes ovarian cancer progression and cisplatin resistance by sponging miR-138-5p to release SDC3 mRNA , 2021, Aging.

[31]  Junhong Han,et al.  The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance , 2021, Cancer drug resistance.

[32]  L. weiswald,et al.  The lncRNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR‐27a‐5p and control of UBE2N levels , 2021, Molecular oncology.

[33]  Maite Huarte,et al.  Gene regulation by long non-coding RNAs and its biological functions , 2020, Nature reviews. Molecular cell biology.

[34]  Zongxian Zhao,et al.  Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer , 2020, Journal of Ovarian Research.

[35]  Zhi-wei Wang,et al.  Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer. , 2020, Seminars in cancer biology.

[36]  L. Hong,et al.  lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway. , 2020, Cancer biotherapy & radiopharmaceuticals.

[37]  Juan-Ying Xu,et al.  Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells , 2020, Archives of Gynecology and Obstetrics.

[38]  Zan-Hui Jia,et al.  Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling , 2020, Scientific Reports.

[39]  Xiaorui Han,et al.  Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis , 2020, Cancer management and research.

[40]  Da Yang,et al.  MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer. , 2020, Molecular carcinogenesis.

[41]  M. Yassin,et al.  Tissue-based long non-coding RNAs "PVT1, TUG1 and MEG3" signature predicts Cisplatin resistance in ovarian Cancer. , 2020, Genomics.

[42]  Jing Cai,et al.  HOTAIR maintains the stemness of ovarian cancer stem cells via the miR-206/TBX3 axis. , 2020, Experimental cell research.

[43]  Xin Wang,et al.  NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis , 2020, Cancer management and research.

[44]  Jing Cai,et al.  HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer , 2020, Cancer Chemotherapy and Pharmacology.

[45]  Yue-Zhen Wang,et al.  Metformin Affects Paclitaxel Sensitivity of Ovarian Cancer Cells Through Autophagy Mediated by Long Noncoding RNASNHG7/miR-3127-5p Axis. , 2020, Cancer biotherapy & radiopharmaceuticals.

[46]  Yan Zhou,et al.  Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells. , 2020, Experimental and molecular pathology.

[47]  Shuheng Bai,et al.  Long non‐coding RNA SNGH7 Is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer , 2020, Journal of cellular and molecular medicine.

[48]  Yun Zhang,et al.  Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1 , 2020, Biological Research.

[49]  Li Li,et al.  LncRNA TLR8-AS1 promotes metastasis and chemoresistance of ovarian cancer through enhancing TLR8 mRNA stability. , 2020, Biochemical and biophysical research communications.

[50]  Hui Zhao,et al.  LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465. , 2020, Journal of biochemistry.

[51]  Na Li,et al.  Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[52]  Y. Assaraf,et al.  Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[53]  Y. Dang,et al.  Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis. , 2020, European review for medical and pharmacological sciences.

[54]  K. Steffensen,et al.  Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer , 2020, Frontiers in Oncology.

[55]  Xueqing Wu,et al.  SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[56]  F. Joly,et al.  The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer. , 2019, Gynecologic oncology.

[57]  Jia Guo,et al.  Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972 , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[58]  Hongxia Li,et al.  Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells. , 2019, Experimental and therapeutic medicine.

[59]  Hao Hu,et al.  Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis , 2019, Journal of Experimental & Clinical Cancer Research.

[60]  G. Lou,et al.  LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis , 2019, Bioscience reports.

[61]  Hanzi Xu,et al.  LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells. , 2019, Cancer biotherapy & radiopharmaceuticals.

[62]  Su Lu,et al.  Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA‐128 and modulating MAPK1 , 2019, Molecular carcinogenesis.

[63]  Cong Shi,et al.  LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1 , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[64]  Jing Jiang,et al.  The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation , 2018, Cell Death & Disease.

[65]  Zhengyan Zhang,et al.  Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[66]  M. Jaggi,et al.  Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. , 2018, Drug discovery today.

[67]  Junbao Liu,et al.  UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. , 2018, Biochemical and biophysical research communications.

[68]  X. Wang,et al.  LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients. , 2018, European review for medical and pharmacological sciences.

[69]  Fanli Shi,et al.  Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. , 2018, Bioscience trends.

[70]  Xiaofeng Xu,et al.  Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway , 2018, Experimental cell research.

[71]  Li Li,et al.  Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer , 2017, Cancer Chemotherapy and Pharmacology.

[72]  H. Yan,et al.  Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. , 2017, Genetics and molecular research : GMR.

[73]  D. Matei,et al.  NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer , 2016, Oncogene.

[74]  R. Mi,et al.  Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. , 2015, International journal of clinical and experimental medicine.

[75]  Brooke L. Fridley,et al.  HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer , 2015, Genome Medicine.

[76]  Jing Jiang,et al.  HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer. , 2015, Molecular medicine reports.